Comparative Pharmacology
Head-to-head clinical analysis: NEXTSTELLIS versus SEASONALE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEXTSTELLIS versus SEASONALE.
NEXTSTELLIS vs SEASONALE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive: estrogen (estetrol) and progestin (drospirenone) suppress gonadotropin release, inhibiting ovulation; increase cervical mucus viscosity, impeding sperm penetration; alter endometrial lining, reducing implantation likelihood.
Seasonale is a combination oral contraceptive containing ethinyl estradiol and levonorgestrel. It suppresses gonadotropin release, inhibiting ovulation, and alters cervical mucus to reduce sperm penetration and endometrial lining to reduce implantation.
One tablet orally once daily, each tablet containing drospirenone 3 mg and estetrol 14.2 mg, taken continuously without a break.
One tablet (0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel) orally once daily for 84 consecutive days, followed by 7 days of placebo.
None Documented
None Documented
Drospirenone: 30 hours; ethinyl estradiol: 12 hours. The long half-life allows once-daily dosing and stable serum concentrations.
Ethinyl estradiol: terminal half-life 13-27 hours (mean 17 hours); levonorgestrel: terminal half-life 11-45 hours (mean 25 hours). Clinical context: Supports once-daily dosing; steady-state achieved within 5-10 days.
Urine (60%) and feces (35%); drospirenone and metabolites, with enterohepatic recirculation.
Renal excretion of metabolites (approximately 50-60% as glucuronide and sulfate conjugates of ethinyl estradiol and levonorgestrel) and fecal elimination (approximately 40-50%).
Category C
Category C
Contraceptive
Contraceptive, Combination Hormonal